Positioning of Esketamine Treatment in the Real-world Management of Depression

PHASE4RecruitingINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

September 15, 2025

Study Completion Date

January 15, 2026

Conditions
Major Depressive Disorder
Interventions
DRUG

Esketamine Nasal Spray [Spravato]

This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.

Trial Locations (1)

2065

RECRUITING

Royal North Shore Hospital, St Leonards

All Listed Sponsors
collaborator

Janssen-Cilag Pty Ltd

INDUSTRY

lead

Royal North Shore Hospital

OTHER